Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells Neonatal cord blood (CB) cells have been demonstrated to contain a high percentage of natural killer (NK) cells, but the NK cells are immature, with a low level of cytolytic activity. However, expression levels of perforin and granzyme have been reported to be high in CB NK cells, and it has been suggested that CB NK cells are phenotypically and functionally mature. It has been suggested that CB is a source of stem cells that is as safe and effective as bone marrow or mobilized peripheral blood. 1, 2 Also, there are a number of progenitor cell populations in CB that can be differentiated to NK cells. Therefore, CB is a useful source to expand NK cells for adoptive immunotherapy, particularly against malignant cells that express a low level of human leukocyte antigen class I molecules. Resting CB NK cells rapidly respond to cytokine stimulation by increasing cytolytic activity. Adoptive transfer of allogeneic NK cells is a potential immunotherapy to induce a graft-versus-leukemia (GVL) effect, without causing a graft-versus-host disease (GVHD). 3 In this study, we tried to expand NK cells from CB with antileukemic activity using good manufacturing practice (GMP)-compliant substances without feeder cells. We used tacrolimus (FK506) and low molecular However, we have reported that tacrolimus enhances the cytolytic activity of inhibitory NK cell receptor (CD94/NKG2A)-expressing CD8T cells. 5 Also, Wang et al. 6 showed that a related compound 
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(cyclosporine A) has essentially no effect on cytolytic activity of NK cells. There is conflicting data on the effect of calcineurin inhibitors on NK cell. Anyways, tacrolimus can inhibit T-cell proliferation. Heparin was reported to bind to several types of cytokines and to activate them, and also to have an important role in the expansion of hematopoietic progenitor cells. 7 Also, heparin sulfate and its related compounds were recognized by natural cytotoxicity receptors such as NKp30, NKp44 and NKp46, and soluble heparin enhanced the secretion of interferon-g by NK cells. 8 Spanholtz et al. 9 reported efficient expansion of NK cells from CB CD34 þ cells, using low molecular weight heparin-based media containing various cytokines. Therefore, we tried to use tacrolimus to inhibit T-cell proliferation and dalteparin to support NK-cell proliferation during NK-cell expansion using IL-2, IL-15 and OKT3 in vitro.
Umbilical CB cells (Hokkaido Cord Blood Bank, Sapporo, Japan; 1 Â 10 6 per ml) were cultured with IL-15 (10 ng/ml; PeproTech Inc., Rocky Hill, NJ, USA), IL-2 (5 ng/ml; R&D Systems, Minneapolis, MN, USA) and anti-CD3 monoclonal antibody (mAb) (OKT3, 10--1000 ng/ml, Janssen Pharmaceutical Company, Tokyo, Japan), with or without tacrolimus (0.02 --0.1 ng/ml, Fujisawa, Osaka, Japan) and dalteparin sodium (Fragmin, 5 --10 U/ml, Pfizer Japan, Tokyo, Japan) in culture medium stem cell growth medium (SCGM) (CeeGenix, Freiburg, Germany), which was produced under GMP, with 5% human AB serum in 24-well plates or T25 flasks without feeder cells. Cell cultures were split approximately one-second to one-fourth after 3 --4 days of culture, and fresh medium, cytokines and reagents were added. After 3 weeks culture of umbilical CB cells (1 Â 10 6 per ml) with IL-15, IL-2 and anti-CD3 mAb without feeder cells, CD56 þ CD3 À NK cells had increased by more than 1000-fold with about 50% purity. Furthermore, addition of dalteparin sodium and tacrolimus efficiently augmented NK cell expansion (1700-fold expansion with 72.8% purity). Also, NK cell proportion was the highest (72.8%) after expansion with both dalteparin sodium and tacrolimus compared with expansion with cytokines only, dalteparin sodium only and tacrolimus only (Table 1 , means±s.d.s, n ¼ 5). The proportion of CD56 þ CD3 À NK cells increased after more than 7 days of culture, and the proportion of CD56-expressing cells increased up to 90% after 3 weeks of culture ( Figure 1a , bars indicate means ± s.d.s, n ¼ 5). Finally, we could obtain about 40 Â 10 6 NK cells from 1 Â 10 6 unmanipulated CB cells under GMP-conditioned medium with 5% human AB serum without feeder cells. Furthermore, this method has also enabled to expand NK cells from adult peripheral blood mononuclear cells (PBMCs; preliminary data not shown).
These expanded NK cells expressed stimulatory NK cell receptor NKG2D and intracellular cytotoxic molecule granzyme (Figure 1b , bars indicate means±s.d.s, n ¼ 5). Also, the expanded CD16 þ CD56 þ NK cells expressed high levels of inhibitory NK receptors, but significantly higher levels of stimulatory NK cell receptors including NKG2C, NKG2D, NKp30, NKp46 and especially, NKp44, than the levels of these receptors on CD16 þ CD56 þ NK cells in resting CB before culture were noted (Figure 1c Cr-labeled K562 human leukemic cell lines, patients' leukemic cells and allogeneic phytohemagglutin (PHA) blasts (5 Â 10 3 ), using standard 4-h 51 Cr release assays. The expanded NK cells had a very high level of cytolytic activity against the K562 leukemic cell line, with specific lysis of more than 50% under the condition of an effector:target ratio (E:T ratio) of 1:1 and more than 80% under the condition of an E:T ratio of 3:1 (Figure 1d) . Also, the expanded NK cells could attack patients' primary acute myeloid leukemia (AML; M0) and chronic myeloid leukemia (CP) leukemic cells, but could not attack allogeneic third-party PHA blasts (Figures 1e and f) . Anti-NKG2D mAb (1D11, 20 mg/ml, Serotec, Oxford, UK) suppressed the cytolytic activity against K562 cells and also patients' primary leukemic cells (Figure 1g) . Therefore, the cytolytic activity of these expanded NK cells depended at least partially on NKG2D-activating receptor.
Allogeneic NK cells have been reported to have a strong GVL effect after haploidentical hematopoietic stem cell transplantation (HSCT) in patients with advanced AML, without causing GVHD. 3 Adoptive transfer of allogeneic NK cells may be a promising immunotherapy. However, expansion of NK cells seems to be difficult compared with expansion of T cells. About 20-fold expansion of NK cells was achieved by culture of PBMCs with cytokines for a short time and co-culture with K562 cells that had been transfected with, and expressed membrane-bound IL-15 and 4-1BBL. These expanded NK cells using artificial feeder cells had cytolytic activity against human AML cells and also pediatric solid tumors such as Ewing sarcoma and rhabdomyosarcoma. On the other hand, there have been several reports of NK cell expansion from PBMCs without using feeder cells. Alici et al. 10 reported the possibility of expanding NK cells without feeder cells from PBMCs of multiple myeloma patients with significant cytolytic activity against primary autologous multiple myeloma cells. It is more beneficial for clinical use if it is not necessary to use feeder cells for efficient expansion of NK cells in vitro. Also, Ayello et al.
11 reported a 20-fold expansion of NK cells from CB cells with depletion of adherent monocytes by ex vivo culture with IL-2, IL-7 and IL-12 for 7 days. Therefore, NK cells can be expanded from not only PBMCs, but also CB.
Clinical-scale NK cell purification has so far been performed by donor leukapheresis followed by CD3 depletion with or without CD56 enrichment. There have been several clinical reports on adoptive transfer of allogeneic NK cells for hematological malignancies. Passweg et al. 12 first reported the feasibility of allogeneic NK cell purification and infusion in five myeloid malignant patients after haploidentical HSCT. Miller et al. 13 reported that haploidentical NK cell infusions after cyclophosphamide and fludarabine treatment resulted in expansion of donor NK cells and induction of complete hematological remission in 5 of 19 AML patients with poor prognosis. A recent pilot study showed good results in pediatric patients who received haploidentical NK cells to consolidate chemotherapy for AML patients. Also, Nguyen et al.
14 reported a persistent and massive expansion of infused alloreactive NK cells in an AML patient who had relapsed after haploidentical HSCT. Yoon et al. 15 reported patients who underwent human leukocyte antigen-mismatched HSCT and subsequently received donor NK cells that were generated from CD34 þ cells from donor leukapheresis products by ex vivo culture for more than 6 weeks (9.3 Â 10 6 per kg, CD122/CD56 þ 64%, CD3 þ 1%). There were no signs of acute toxicity in 14 adult patients infused with these cells 6 --7 weeks after transplantation, with one patient developing acute GVHD and five patients developing chronic GVHD. Therefore, clinical-grade allogeneic NK cell infusion is safe and feasible. However, many issues remain to be resolved, including selection of donor, NK cell selection and expansion procedure, type of conditioning regimen, survival and expansion of NK cells in the recipient after infusion, their localization and finally, the clinical effect of NK cell infusion.
In this study, we could obtain about 40 Â 10 6 NK cells from 1 Â 10 6 unmanipulated CB cells using tacrolimus and dalteparin sodium without feeder cells (more than 1000-fold expansion with more than 70% purity). Thus, alloreactive Killer cell immunoglobulin-like receptor (KIR)-mismatched expanded NK cells from CB can be used for adoptive NK cell immunotherapy to induce a strong GVL/tumor effect without severe GVHD for patients who do not have KIR-mismatched related donors.
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